AngioDynamics (ANGO) Reports Q1 EPS of $0.17

AngioDynamics (NASDAQ: ANGO) reported Q1 EPS of $0.17, versus $0.11 reported last year. Revenue for the quarter came in at $88.1 million, versus $83.8 million reported last year.

The Company announced its FY2017 guidance will remain unchanged, with net sales guidance of $355 million to $360 million and adjusted EPS of $0.62 to $0.65. The Company reiterated its FY2017 free cash flow guidance of greater than $30 million.

For earnings history and earnings-related data on AngioDynamics (ANGO) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c